Pyxis Oncology Finalizes $110M Offering with Warrants at $3.50 Exercise Price
PYXS has more than doubled off its 52-week low of $1.03 on elevated volume (6.7× avg).
Summary
A $110 million offering of common stock and warrants has been priced by Pyxis Oncology, with net proceeds of $102.8 million to fund its lead ADC program MICVO through Phase 3. The warrants carry a $3.50 exercise price and require stockholder approval of a charter amendment before they can be exercised.
Updates
· SEC 8-K — The offering closed on October 1, 2026, with net proceeds of approximately $102.8 million.
Key Events · Financing and Capital Events · PYXS
-
$110M Offering Priced at $2.90
36,047,919 shares plus 1,883,121 pre-funded warrants sold at $2.90 per unit, raising $109,998,133 gross before $6.6M underwriting discounts and $600K expenses.
-
Warrants Add 49.3M Potential Shares
Each share or pre-funded warrant comes with a common warrant to buy 1.3 shares at $3.50 per share — 49,310,352 total warrant shares, exercisable only after stockholder approval of a charter amendment.
-
Charter Amendment Risk
Company lacks sufficient authorized shares for warrant exercise; must hold stockholder votes every 60 days until approval. If approval fails, warrants may have zero value.
-
Runway Extended to H1 2028
Net proceeds of $102.8M extend cash runway into first half of 2028, but without warrant exercise, funds are insufficient to fully fund the Phase 3 Headliner trial.
Analysis · PYXS · Life Sciences
A $110 million public offering has been finalized by Pyxis Oncology, comprising 36 million shares at $2.90 each and paired common warrants exercisable at $3.50 per share. Exercise of the warrants hinges on stockholder approval of a charter amendment to increase authorized shares — a condition that introduces real risk the warrants could expire worthless if approval fails. Net proceeds of $102.8 million extend the cash runway into the first half of 2028, yet the company states plainly that without warrant exercise, the funds are insufficient to fully fund the planned Phase 3 Headliner trial for MICVO. This is a survival financing for a clinical-stage biotech with a going-concern warning, priced at a modest discount to the last reported sale price of $2.90 on September 29, 2026.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 35.7% of the 1024 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PYXS was trading at $2.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $194.3M. The 52-week trading range was $1.03 to $5.55. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.